CSPC Wins U.S. FDA Nod for Monthly GLP-1/GIP Obesity Injection Trial

CSPC Pharmaceutical Group ( (HK:1093) ) has issued an update.

CSPC Pharmaceutical Group has received U.S. FDA approval to begin clinical trials of its GLP-1/GIP receptor dual-biased agonist SYH2082, a once-monthly long-acting injection for weight management in obese or overweight individuals with weight-related comorbidities. The candidate, built on CSPC’s long-acting platforms, showed superior and sustained weight-loss efficacy with good tolerability in preclinical studies, positioning the company to strengthen its innovation capabilities in metabolic diseases and potentially broaden into type 2 diabetes treatment.

By securing U.S. clinical clearance for SYH2082, CSPC advances a key pipeline asset that could compete with existing incretin-based obesity drugs if successful, enhancing its standing in the global metabolic treatment market. The trial marks a strategic milestone that may lay the groundwork for a broader portfolio of long-acting metabolic therapies, with implications for patients seeking more convenient dosing and for CSPC’s long-term growth in high-value chronic disease segments.

The most recent analyst rating on (HK:1093) stock is a Hold with a HK$10.70 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on developing innovative therapies, leveraging proprietary long-acting formulation and half-life extension technologies. The group targets major therapeutic areas including metabolic diseases, aiming to expand its presence in global markets such as the U.S. through advanced biologic and peptide-based drugs.

YTD Price Performance: 19.93%

Average Trading Volume: 121,949,988

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$116.3B

For a thorough assessment of 1093 stock, go to TipRanks’ Stock Analysis page.